Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well ...

Following a slump in August, which posted the lowest med-tech deal values of 2024, September bounced back with the highest ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance ...

Ceribell Inc. launched its initial public offering of more than 10.6 million shares of common stock at $17 and steadily saw ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Glooko Inc. secured a $100 million series F financing to support expansion of its diabetes ecosystem platform, which ...

Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular ...

The founding CEO of Alnylam Pharmaceuticals Inc. is now leading the charge with newly launched City Therapeutics Inc., which just completed a $135 million series A financing. City’s executive chair, ...

Endostart s.r.l obtained CE marking for the expanded use of its magnetic balloon system for use in endoscopic procedures, Endorail, to enteroscopy. The company believes that Endorail, which helps ...

It’s hard to know where to start in describing the biopharma applications of the 2024 Nobel Prize in Physics. It was awarded ...

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.